Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-1

6

Cyclooxygenase-2

6

Interleukin-8 receptors, CXCR1/CXCR2

6

N-acylsphingosine-amidohydrolase

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1986

6

1996

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Migraine

6

Musculoskeletal pain

6

Osteoarthritis

6

Pain

6

Pain, postoperative

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Rhône-Poulenc

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

EVMPD

7

FDA UNII

7

PUBCHEM

7

SMS_ID

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

MUSCULO-SKELETAL SYSTEM

2

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

2

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

2

ANALGESICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

2

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

2

OPIOIDS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiinflammatory preparations, non-steroids for topical use

2

Propionic acid derivatives

2

Opioids in combination with non-opioid analgesics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DEXKETOPROFEN

6KD9E78X68

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

Isopropyl palmitate

8CRQ2TH63M

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

N-acylsphingosine-amidohydrolase

Conditions:

Isopropyl palmitate is the ester of isopropyl alcohol and palmitic acid. It is an emollient, moisturizer, thickening agent, and anti-static agent. Isopropyl Palmitate is a traditional, fast spreading emollient for modern cosmetic applications. Isopro...

pyl palmitate is approved by ECOCERT for Natural and Organic Cosmetics. It is on FDA CFR - Code of Federal Regulations Title 21 list.

KETOPROFEN ARGININE

029SOQ8920

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

DEXKETOPROFEN TROMETHAMINE

N674F7L21E

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

KETOPROFEN LYSINE

5WD00E3D4C

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

KETOPROFEN SODIUM

5R10M39KS7

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

KETOPROFEN

90Y4QC304K

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1